Fennec Pharmaceuticals, Inc. (FENC) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Knight Therapeutics, Inc.

Fennec Pharmaceuticals, Inc.

BioSyent, Inc.

HLS Therapeutics, Inc.

InnoCan Pharma Corp.

Ayr Wellness, Inc.

NervGen Pharma Corp.

Defence Therapeutics Inc

Arch Biopartners, Inc.

Cybin, Inc.

Mindset Pharma, Inc.

Why is Fennec Pharmaceuticals, Inc. ?

With a growth in Net Sales of 65.05%, the company declared Outstanding results in Mar 26

NET SALES(Q) Highest at CAD 20.72 MM
RAW MATERIAL COST(Y) Fallen by -0.52% (YoY)
CASH AND EQV(HY) Highest at CAD 106.5 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 19.04%, its profits have risen by 51.6%

High Institutional Holdings at 61.62%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Their stake has increased by 4.95% over the previous quarter.

Underperformed the market in the last 1 year

The stock has generated a return of 19.04% in the last 1 year, much lower than market (S&P/TSX 60) returns of 29.60%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Fennec Pharmaceuticals, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Fennec Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Fennec Pharmaceuticals, Inc.

19.04%

1.51

66.01%

S&P/TSX 60

29.6%

2.31

12.81%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

134.72%

EBIT Growth (5y)

10.74%

EBIT to Interest (avg)

-11.26

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.78

Sales to Capital Employed (avg)

2.11

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

61.62%

ROCE (avg)

ROE (avg)

18.98%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.95

EV to EBIT

-30.50

EV to EBITDA

-30.63

EV to Capital Employed

-73.42

EV to Sales

3.64

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-17.73%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

25What is working for the Company

NET SALES(Q)

Highest at CAD 20.72 MM

RAW MATERIAL COST(Y)

Fallen by -0.52% (YoY

CASH AND EQV(HY)

Highest at CAD 106.5 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 2.38 times

OPERATING PROFIT(Q)

Highest at CAD -0.13 MM

OPERATING PROFIT MARGIN(Q)

Highest at -0.62 %

PRE-TAX PROFIT(Q)

Highest at CAD 0.28 MM

NET PROFIT(Q)

Highest at CAD 0.28 MM

EPS(Q)

Highest at CAD 0.01

-2What is not working for the Company

ROCE(HY)

Lowest at -55.04%

Here's what is working for Fennec Pharmaceuticals, Inc.

Net Sales

Highest at CAD 20.72 MM and Grown

In each period in the last five periods

MOJO Watch

Near term sales trend is very positive

Net Sales (CAD MM)

Pre-Tax Profit

At CAD 0.28 MM has Grown at 116.51%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CAD MM)

Net Profit

At CAD 0.28 MM has Grown at 116.51%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CAD MM)

Net Sales

At CAD 20.72 MM has Grown at 65.05%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CAD MM)

Operating Profit

Highest at CAD -0.13 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CAD MM)

Operating Profit Margin

Highest at -0.62 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at CAD 0.28 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CAD MM)

Net Profit

Highest at CAD 0.28 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CAD MM)

EPS

Highest at CAD 0.01

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CAD)

Cash and Eqv

Highest at CAD 106.5 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio

Highest at 2.38 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -0.52% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales